Commentary: Aβ(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels

Experimental Neurology

Volumn 212, Issue 2, 2008, Pages 251-254

  Lanctôt, Krista L ^a,b   Herrmann, Nathan ^a,b   Rothenburg, Lana S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; NERVE GROWTH FACTOR; SEROTONIN 2A RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CELL ACTIVATION; CELL LOSS; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; EPISODIC MEMORY; GENE MUTATION; HUMAN; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NERVE CELL LESION; NERVE CELL PLASTICITY; NERVE SPROUTING; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROCESSING; SECOND MESSENGER; SENILE PLAQUE; SEROTONIN BLOOD LEVEL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPY EFFECT; TREATMENT RESPONSE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HIPPOCAMPUS; METABOLISM; NOTE;

AMYLOID BETA-PROTEIN; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBRAL CORTEX; HIPPOCAMPUS; MEMORY DISORDERS; PEPTIDE FRAGMENTS; RECEPTOR, SEROTONIN, 5-HT2A;

EID: 48949115580     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.04.031     Document Type: Note

References (51)

1. Atamna H., and Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3381-3386
2. Blin J., Baron J.C., Dubois B., Crouzel C., Fiorelli M., Attar-Levy D., Pillon B., Fournier D., Vidailhet M., and Agid Y. Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. Brain 116 Pt 3 (1993) 497-510
3. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991) 239-259
4. Burbach G.J., Hellweg R., Haas C.A., Del Turco D., Deicke U., Abramowski D., Jucker M., Staufenbiel M., and Deller T. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J. Neurosci. 24 (2004) 2421-2430
5. Butterfield D.A., and Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32 (2002) 1050-1060
6. Chen L., Yamada K., Nabeshima T., and Sokabe M. alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 50 (2006) 254-268
7. Christensen, D.D., 2007. Alzheimer's disease: progress in the development of anti-amyloid disease-modifying therapies. CNS Spectr. 12, 113-116, 119-123.
8. Christensen R., Marcussen A.B., Wortwein G., Knudsen G.M., and Aznar S. Abeta((1-42)) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Exp. Neurol. 210 (2008) 164-171
9. Connor B., Young D., Yan Q., Faull R.L., Synek B., and Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res. Mol. Brain Res. 49 (1997) 71-81
10. D'Andrea M.R., and Nagele R.G. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr. Pharm. Des. 12 (2006) 677-684
11. Dewar D., Graham D.I., and McCulloch J. 5 HT2 receptors in dementia of Alzheimer type: a quantitative autoradiographic study of frontal cortex and hippocampus. J. Neural. Transm. Park Dis. Dement Sect. 2 (1990) 129-137
12. Eriksdotter Jonhagen M., Nordberg A., Amberla K., Backman L., Ebendal T., Meyerson B., Olson L., Seiger, Shigeta M., Theodorsson E., Viitanen M., Winblad B., and Wahlund L.O. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9 (1998) 246-257
13. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., and Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 366 (2005) 2112-2117
14. Garzon D.J., and Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J. Neurosci. 27 (2007) 2628-2635
15. Gonzalo-Ruiz A., Gonzalez I., and Sanz-Anquela J.M. Effects of beta-amyloid protein on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. J. Chem. Neuroanat. 26 (2003) 153-169
16. Graff-Radford N.R., Crook J.E., Lucas J., Boeve B.F., Knopman D.S., Ivnik R.J., Smith G.E., Younkin L.H., Petersen R.C., and Younkin S.G. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 64 (2007) 354-362
17. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
18. Hasselbalch S.G., Madsen K., Svarer C., Pinborg L.H., Holm S., Paulson O.B., Waldemar G., and Knudsen G.M. Reduced 5-HT(2A) receptor binding in patients with mild cognitive impairment. Neurobiol. Aging. (2007) [Epub ahead of print]
19. Herrmann N., Lanctôt K.L., Eryavec G., Van Reekum R., and Khan L.R. Growth hormone response to clonidine predicts aggression in Alzheimer's disease. Psychoneuroendocrinology 29 (2004) 1192-1197
20. Kimura N., Takahashi M., Tashiro T., and Terao K. Amyloid beta up-regulates brain-derived neurotrophic factor production from astrocytes: rescue from amyloid beta-related neuritic degeneration. J. Neurosci. Res. 84 (2006) 782-789
21. Lai M.K., Tsang S.W., Alder J.T., Keene J., Hope T., Esiri M.M., Francis P.T., and Chen C.P. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology (Berl) 179 (2005) 673-677
22. Lanctôt K.L., Herrmann N., Black S.E., Ryan M., Rothenburg L.S., and Busto U.E. Apathy associated with Alzheimer's disease: use of dextroamphetamine challenge. Am. J. Ger. Psychiatry 16 7 (2008) 551-557
23. Lanctôt K.L., Herrmann N., and Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J. Neuropsychiatry Clin. Neurosci. 13 (2001) 5-21
24. Lanctôt K.L., Herrmann N., Rothenburg L., and Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer's disease. Int. Psychogeriatr. 19 (2007) 151-158
25. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Schott K., Langer H., and Gawaz M. Decreased brain-derived neurotrophic factor (BDNF)- and beta-thromboglobulin (beta-TG)-blood levels in Alzheimer's disease. Thromb. Haemost. 96 (2006) 102-103
26. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Wittorf A., Richartz E., Bartels M., Buchkremer G., and Schott K. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J. Neural. Transm. 113 (2006) 1217-1224
27. Leyhe T., Stransky E., Eschweiler G.W., Buchkremer G., and Laske C. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 258 (2008) 124-128
28. Liu Z., Ma D., Feng G., Ma Y., and Hu H. Recombinant AAV-mediated expression of human BDNF protects neurons against cell apoptosis in Abeta-induced neuronal damage model. J. Huazhong Univ. Sci. Technolog. Med. Sci. 27 (2007) 233-236
29. Lorke D.E., Lu G., Cho E., and Yew D.T. Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 7 (2006) 36
30. Mattson M.P., Maudsley S., and Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 27 (2004) 589-594
31. Meltzer C.C., Price J.C., Mathis C.A., Greer P.J., Cantwell M.N., Houck P.R., Mulsant B.H., Ben-Eliezer D., Lopresti B., DeKosky S.T., and Reynolds III C.F. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am. J. Psychiatry 156 (1999) 1871-1878
32. Meyer J.H., Kapur S., Eisfeld B., Brown G.M., Houle S., DaSilva J., Wilson A.A., Rafi-Tari S., Mayberg H.S., and Kennedy S.H. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am. J. Psychiatry 158 (2001) 78-85
33. Michalski B., and Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Brain Res. Mol. Brain Res. 111 (2003) 148-154
34. Pangalos M.N., Jacobsen S.J., and Reinhart P.H. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. Biochem. Soc. Trans. 33 (2005) 553-558
35. Parent M.B., and Baxter M.G. Septohippocampal acetylcholine: involved in but not necessary for learning and memory?. Learn. Mem. 11 (2004) 9-20
36. Peng S., Wuu J., Mufson E.J., and Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem. 93 (2005) 1412-1421
37. Phillips H.S., Hains J.M., Armanini M., Laramee G.R., Johnson S.A., and Winslow J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7 (1991) 695-702
38. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., and Rowe C.C. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130 (2007) 2837-2844
39. Reinikainen K.J., Paljarvi L., Huuskonen M., Soininen H., Laakso M., and Riekkinen P.J. A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J. Neurol. Sci. 84 (1988) 101-116
40. Sambrook R., Herrmann N., Hebert R., McCracken P., Robillard A., Luong D., and Yu A. Canadian Outcomes Study in Dementia: study methods and patient characteristics. Can J. Psychiatry 49 (2004) 417-427
41. Schulte-Herbruggen O., Braun A., Rochlitzer S., Jockers-Scherubl M.C., and Hellweg R. Neurotrophic factors-a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?. Curr. Med. Chem. 14 (2007) 2318-2329
42. Snyder S.H., Faillace L., and Hollister L. 2,5-dimethoxy-4-methyl-amphetamine (STP): a new hallucinogenic drug. Science 158 (1967) 669-670
43. Song J., Hanniford D., Doucette C., Graham E., Poole M.F., Ting A., Sherf B., Harrington J., Brunden K., and Stricker-Krongrad A. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes. Assay Drug Dev. Technol. 3 (2005) 649-659
44. Szapacs M.E., Numis A.L., and Andrews A.M. Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiol. Dis. 16 (2004) 572-580
45. Tang Y., Yamada K., Kanou Y., Miyazaki T., Xiong X., Kambe F., Murata Y., Seo H., and Nabeshima T. Spatiotemporal expression of BDNF in the hippocampus induced by the continuous intracerebroventricular infusion of beta-amyloid in rats. Brain Res. Mol. Brain Res. 80 (2000) 188-197
46. Tong L., Balazs R., Thornton P.L., and Cotman C.W. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J. Neurosci. 24 (2004) 6799-6809
47. Traissard N., Herbeaux K., Cosquer B., Jeltsch H., Ferry B., Galani R., Pernon A., Majchrzak M., and Cassel J.C. Combined damage to entorhinal cortex and cholinergic basal forebrain neurons, two early neurodegenerative features accompanying Alzheimer's disease: effects on locomotor activity and memory functions in rats. Neuropsychopharmacology 32 (2007) 851-871
48. Tuszynski M.H., Thal L., Pay M., Salmon D.P., U,H.S., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., and Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11 (2005) 551-555
49. Versijpt J., Van Laere K.J., Dumont F., Decoo D., Vandecapelle M., Santens P., Goethals I., Audenaert K., Slegers G., Dierckx R.A., and Korf J. Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings. Neurobiol. Aging 24 (2003) 553-561
50. Wimo A., Winblad B., Aguero-Torres H., and von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord. 17 (2003) 63-67
51. Yasutake C., Kuroda K., Yanagawa T., Okamura T., and Yoneda H. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur. Arch. Psychiatry Clin. Neurosci. 256 (2006) 402-406